113 related articles for article (PubMed ID: 15538115)
1. Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis.
Chu QD; Hurd TC; Harvey S; Martinick M; Markus G; Tan D; Gibbs JF; Loree T
Diagn Mol Pathol; 2004 Dec; 13(4):241-6. PubMed ID: 15538115
[TBL] [Abstract][Full Text] [Related]
2. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
3. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
4. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
6. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells.
Nowicki TS; Kummer NT; Iacob C; Suslina N; Schaefer S; Schantz S; Shin E; Moscatello AL; Tiwari RK; Geliebter J
Laryngoscope; 2010 Jul; 120(7):1383-90. PubMed ID: 20578104
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Ulisse S; Baldini E; Toller M; Marchioni E; Giacomelli L; De Antoni E; Ferretti E; Marzullo A; Graziano FM; Trimboli P; Biordi L; Curcio F; Gulino A; Ambesi-Impiombato FS; D'Armiento M
Eur J Cancer; 2006 Oct; 42(15):2631-8. PubMed ID: 16928445
[TBL] [Abstract][Full Text] [Related]
9. In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.
Sordat I; Chaubert P; Protiva P; Guillou L; Mazzucchelli L; Saraga E; Benhattar J; Trân-Thang C; Blum AL; Dorta G; Sordat B
Am J Pathol; 1997 Jan; 150(1):283-95. PubMed ID: 9006343
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
11. uPA receptor expression in benign and malignant thyroid tumors.
Kim SJ; Shiba E; Taguchi T; Tsukamoto F; Miyoshi Y; Tanji Y; Takai S; Noguchi S
Anticancer Res; 2002; 22(1A):387-93. PubMed ID: 12017319
[TBL] [Abstract][Full Text] [Related]
12. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
Zanetti A; Stoppacciaro A; Marzullo A; Ciabatta M; Fazioli F; Prat M; Comoglio PM; Baroni CD; Ruco LP
J Pathol; 1998 Nov; 186(3):287-91. PubMed ID: 10211118
[TBL] [Abstract][Full Text] [Related]
13. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
Nielsen A; Scarlett CJ; Samra JS; Gill A; Li Y; Allen BJ; Smith RC
J Gastroenterol Hepatol; 2005 Feb; 20(2):256-63. PubMed ID: 15683429
[TBL] [Abstract][Full Text] [Related]
14. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
15. Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis.
Chai YJ; Kim YA; Jee HG; Yi JW; Jang BG; Lee KE; Park YJ; Youn YK
Surgery; 2014 Dec; 156(6):1559-67; discussion 1567-8. PubMed ID: 25456955
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens.
Giannini R; Faviana P; Cavinato T; Elisei R; Pacini F; Berti P; Fontanini G; Ugolini C; Camacci T; De Ieso K; Miccoli P; Pinchera A; Basolo F
Thyroid; 2003 Aug; 13(8):765-70. PubMed ID: 14558920
[TBL] [Abstract][Full Text] [Related]
18. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
[TBL] [Abstract][Full Text] [Related]
19. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
20. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte HJ; Schmitt M
Histochem Cell Biol; 1998 Jul; 110(1):27-32. PubMed ID: 9681686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
